The Efficacy of the Drug Epoprostenol in the Treatment of Pulmonary Hypertension Associated with Scleroderma
Journal: Annals of Internal Medicine (2000)

Summaries for Patients21 March 2000The Efficacy of the Drug Epoprostenol in the Treatment of Pulmonary Hypertension Associated with SclerodermaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00027 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Pulmonary hypertension (high blood pressure in the arteries that go to the lungs) can produce disabling shortness of breath and often causes death. It can occur on its own (primary pulmonary hypertension) but is usually the result of an underlying lung disease, such as scleroderma (secondary pulmonary hypertension). No proven therapies for pulmonary hypertension are known, but epoprostenol, a drug that can dilate narrowed arteries, has shown promise in the treatment of patients with primary pulmonary hypertension.Why did the researchers do this particular study?The researchers wanted ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. A Randomized, Controlled Trial.”. It is in the 21 March 2000 issue of Annals of Internal Medicine (volume 132, pages 425-433). The authors are D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, J.E. Loyd, S. Murali, A. Frost, R. Girgis, R.C. Bourge, D.D. Ralph, C.G. Elliott, N.S. Hill, D. Langleben, R.J. Schilz, V.V. McLaughlin, I.M. Robbins, B.M. Groves, S. Shapiro, T.A. Medsger Jr., S.P. Gaine, E. Horn, J.C. Decker, and K. Knob.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoContinuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease David B. Badesch , Victor F. Tapson , Michael D. McGoon , Bruce H. Brundage , Lewis J. Rubin , Fredrick M. Wigley , Stuart Rich , Robyn J. Barst , Pamela S. Barrett , Kenneth M. Kral , Maria M. Jöbsis , James E. Loyd , Srinivas Murali , Adaani Frost , Reda Girgis , Robert C. Bourge , David D. Ralph , C. Gregory Elliott , Nicholas S. Hill , David Langleben , Robert J. Schilz , Vallerie V. McLaughlin , Ivan M. Robbins , Bertron M. Groves , Shelley Shapiro , Thomas A. Medsger Jr. , Sean P. Gaine , Evelyn Horn , James C. Decker , and Katharine Knobil Metrics 21 March 2000Volume 132, Issue 6Page: 425KeywordsArteriesDyspneaExerciseLungsPatientsPrimary hypertensionPulmonary diseasesPulmonary hypertensionSclerodermaVeins ePublished: 15 August 2000 Issue Published: 21 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...